Eckert & Ziegler Strahlen- und Medizintechnik AG

Earnings Release • Nov 6, 2012

News Details

Corporate | 6 November 2012 07:50

Eckert & Ziegler Q3/2012: Sales and Earnings in line. Increases in Earnings confirmed for 2013.

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Quarter Results

06.11.2012 / 07:50

---

Berlin, 6 November 2012. For Eckert & Ziegler AG, one of the leading
manufacturers of isotope products for medicine, science and industry (ISIN
DE0005659700), the first nine months of 2012 continued to be successful.
Compared with the same period for the previous year, sales rose by 5% to 88
million EUR. Profit after taxes and minority interests achieved 7.1
million EUR or 1.34 EUR per share. This was therefore approx. 1.7 million
EUR or 0.34 EUR per share below the value for the previous year. The main
cause for this are the extraordinary expenses for the acquisition and
incorporation of Eckert Ziegler Vitalea Inc., as well as the cost of
aborting a very far advanced acquisition project, which was rejected after
extensive examination. For the financial year 2012, the forecast profit
remains unchanged at 1.95 EUR per share. A 20% increase in earnings to
approx. 2.35 EUR per share is still expected for 2013.

The Isotope Products segment made the largest contribution to the overall
result of the third quarter. Here sales revenues with external customers
rose slightly by 1% to EUR 41.5 million. The aforementioned advantageous
change in the exchange rate was the strongest in this segment, so that
sales revenues remained constant - to somewhat simplify. Production and
sales costs developed in proportion to sales revenues. However,
administrative costs increased slightly, so that EBIT for the segment
declined by EUR 0.4 million or 3% to EUR 12.6 million.

The Radiation Therapy segment posted exceptionally high sales figures for
the new MultiSource(R) cancer radiation device in the third quarter.
During the nine-month period, sales revenues rose by 12% to EUR 21.8
million. Due to changes in the product mix production costs increased more
sharply than sales revenues, while sales costs declined slightly after the
successful market launch. Overall, EBIT remained constant at EUR 1.9
million compared to the same period the previous year. Extensive
information on the Radiation Therapy segment can also be found in Eckert &
Ziegler BEBIG s.a. quarterly report, which is being published
simultaneously (www.bebig.eu).

The Radiopharma segment has continued to grow at a moderate rate. Sales
revenues increased by 4% to EUR 19.9, which is mainly due to the basis
effect from the Bioscan acquisition in mid-2011. As compared to the same
period of the previous year, expenditures for production and sales
increased. Therefore, EBIT declined by 31% to EUR 2.2 million.

The strongest growth was posted by the Environmental Services segment.
Sales revenues from external customers rose by 13% to EUR 4.6 million. As
in the second quarter, provisions for the removal of old waste were also
adjusted in the third quarter. This resulted in extraordinary expenditures,
such that EBIT now shows a loss of EUR -1.3 million.

To read the full quarterly report please click here:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz312e.pdf

The Group anticipates sales revenues of about EUR 117 million and results
of about EUR 10 million after taxes and minority interests in fiscal year
2012. For 2013, the budget plan, which has already been completed, projects
a significant increase in sales revenues to EUR 125 million and an even
higher increase in results after taxes and minority interests to EUR 12
million, provided that the average annual Euro/US dollar exchange rate does
not rise above the current level of 1.30 USD per EUR.

With more than 600 employees the Eckert & Ziegler Group belongs to the
largest providers of isotope components for radiotherapy and nuclear
medicine worldwide.

If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de

End of Corporate News

---

06.11.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München

End of News DGAP News-Service

191559 06.11.2012